MAY 12, 2016 07:30 AM PDT
The molecular analysis on circulating tumor cells to determine prognostic and predictive factors in cancer research
Presented at the Genetics and Genomics Virtual Event
CONTINUING EDUCATION (CME/CE/CEU) CREDITS: P.A.C.E. CE
6 20 194

Speakers:
  • Director, Liquid Biopsy and Site Manager, QIAGEN Hannover Germany
    Biography
      Dr. Siegfried Hauch studied biology at the Albert Einstein University in Ulm and received his PhD 1997 in plant physiology and molecular biology at the Eberhard Karls University Tübingen. Until 2001 he was Product Manager for imaging systems and microarray technologies at Biozym Diagnostics GmbH and changed therafter to AdnaGen AG as Marketing Manager in 2001. In addition to his marketing responsibilities he was director of R&D since 2006 to build, secure and enhance the AdnaGen circulating tumor cell business and, after the accquistion by Alere Inc. in 2010, he was holding the position as CSO and General Manager at Alere/AdnaGen GmbH. Since 2015 Dr. Hauch serves as Director of Liquid Biopsy and Site Manager at QIAGEN Hannover GmbH.

    Abstract:
    Circulating tumor cells (CTCs) is an emerging source used molecular cancer diagnostics. Through expression profiling of CTCs, it allows a deeper understanding about which metabolic pathways enable tumor cells to survive in the circulation, how they become resistant to a drug regimen, how they transform and adapt and, finally, which cellular markers should targeted for future therapies. 
    This webinar will introduce the AdnaTest CTC detection platform which has been proven in several clinical trials to provide prognostic and predictive information in breast, ovarian and prostate cancer. The platform by itself is still open for research and allows access to any potential target of interest. Join us to learn more about this novel platform, its technology and applications in liquid biopsy.

    Show Resources
    Loading Comments...